MED
Medifast, Inc.
MED has lower modeled downside risk, despite its lower overall score.
RIVN
Rivian Automotive, Inc.
RIVN has the edge over MED overall, supported by stronger fundamentals and stronger modeled upside.
MED Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
MED's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
RIVN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
RIVN's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
MED PE Valuation
MED has no meaningful PE right now: it lost money over the past year.
RIVN PE Valuation
RIVN has no meaningful PE right now: it lost money over the past year.
MED Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MED's losses to shrink, with revenue holding steady.
RIVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
RIVN has the edge over MED on the outlook, with more favorable revenue expectations.
MED Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.68 | -18500% |
| Q2 2026 | -$2.32 | -803% |
| Q1 2026 | -$1.82 | -$1.18 |
| Q4 2025 | -$1.70 | -995% |
| Q3 2025 | $0.02 | -97% |
| Q2 2025 | $0.33 | -88% |
| Q1 2025 | -$0.64 | -110% |
| Q4 2024 | $0.19 | -98% |
MED has swung to a loss: it lost $3.68 per share over the past year, after a profit the year before.
RIVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.25 | +$0.83 |
| Q2 2026 | -$2.58 | +$0.62 |
| Q1 2026 | -$2.92 | +$0.77 |
| Q4 2025 | -$3.07 | +$1.62 |
| Q3 2025 | -$3.08 | +$2.52 |
| Q2 2025 | -$3.20 | +$2.76 |
| Q1 2025 | -$3.69 | +$2.08 |
| Q4 2024 | -$4.69 | +$1.05 |
RIVN has the edge over MED on earnings, with more consistent year-over-year improvement.
MED Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $72M | -19% |
| Q2 2026 | $76.4M | -28% |
| Q1 2026 | $76M | -34% |
| Q4 2025 | $75.1M | -37% |
| Q3 2025 | $89.4M | -36% |
| Q2 2025 | $105.6M | -37% |
| Q1 2025 | $115.7M | -34% |
| Q4 2024 | $119M | -38% |
MED's revenue has slid since its 2022 peak: $72M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -27% | -22 points |
| Q2 2026 | -5.7% | -4.7 points |
| Q1 2026 | -4.3% | -3.2 points |
| Q4 2025 | -10% | -11 points |
| Q3 2025 | -4.6% | -6.1 points |
| Q2 2025 | -1% | +3.7 points |
| Q1 2025 | -1.1% | -5.6 points |
| Q4 2024 | 0.6% | -3.9 points |
MED has the edge over RIVN on profitability, with a higher operating margin.
RIVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2B | +38% |
| Q2 2026 | $1.7B | +27% |
| Q1 2026 | $1.4B | +11% |
| Q4 2025 | $1.3B | -26% |
| Q3 2025 | $1.6B | +78% |
| Q2 2025 | $1.3B | +13% |
| Q1 2025 | $1.2B | +3% |
| Q4 2024 | $1.7B | +32% |
RIVN has the edge over MED on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -41% | +22 points |
| Q2 2026 | -50% | +35 points |
| Q1 2026 | -64% | -11 points |
| Q4 2025 | -65% | -27 points |
| Q3 2025 | -63% | +71 points |
| Q2 2025 | -86% | +33 points |
| Q1 2025 | -53% | +70 points |
| Q4 2024 | -38% | +82 points |
RIVN's operating margin was −41% last quarter, up 22 points from the same quarter a year ago, near the top of its range since 2021.
MED Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.9M | -73% |
| Q2 2026 | $728K | +$5.5M |
| Q1 2026 | -$836K | -144% |
| Q4 2025 | -$6.6M | +$603K |
| Q3 2025 | $10.8M | +40% |
| Q2 2025 | -$4.8M | -143% |
| Q1 2025 | $1.9M | -65% |
| Q4 2024 | -$7.2M | -176% |
MED's free cash flow has turned negative after years in the green: −$4M over the past year.
RIVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.1B | -$703M |
| Q2 2026 | -$849M | -$451M |
| Q1 2026 | -$1.1B | -$549M |
| Q4 2025 | -$1.1B | -234% |
| Q3 2025 | -$421M | +$732M |
| Q2 2025 | -$398M | +$639M |
| Q1 2025 | -$526M | +$997M |
| Q4 2024 | $856M | +$2.3B |
RIVN has the edge over MED on cash flow, with more consistent year-over-year improvement.
MED Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +46K shares |
| 1 year | +1.7% | +190K shares |
| 3 years | +2.3% | +248K shares |
| 5 years | -5.1% | -604K shares |
| Available history | -7.7% | -936K shares |
MED has the edge over RIVN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | $3.6M |
RIVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.1% | +121M shares |
| 1 year | +19% | +226M shares |
| 3 years | +52% | +494M shares |
RIVN has 1.4B diluted shares, up 19% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | $6M |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MED Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -2,976.8x | Net Cash |
| Q3 2025 | -12.1x | Net Cash |
| Q2 2025 | -7.2x | Net Cash |
| Q1 2025 | -14.3x | Net Cash |
| Q4 2024 | -5.8x | Net Cash |
| Q3 2024 | -4.9x | Net Cash |
| Q2 2024 | -2.3x | Net Cash |
| Q1 2024 | -1.0x | Net Cash |
MED has more cash than debt.
RIVN Net Leverage
RIVN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MED Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.1 | Neutral |
| Stochastic | 72.6 | Neutral |
MED's weekly RSI is 59 (neutral) and its Stochastic is 73 (neutral).
RIVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.5 | Neutral |
| Stochastic | 25.6 | Neutral |
RIVN's weekly RSI is 41 (neutral) and its Stochastic is 26 (neutral).
MED PE vs Consumer Cyclical Sector
| Metric | MED | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
MED has no meaningful PE right now: it lost money over the past year.
RIVN PE vs Consumer Cyclical Sector
RIVN has no meaningful PE right now: it lost money over the past year.
MED Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.1 | 6% above |
| 20 week MA | $11.7 | 10% above |
| 50 week MA | $11.4 | 13% above |
| 100 week MA | $12.6 | 1.9% above |
| 200 week MA | $35.4 | 64% below |
MED has the edge over RIVN on trend strength, trading above more of its moving averages.
RIVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.3 | 3.9% below |
| 20 week MA | $15.1 | 15% below |
| 50 week MA | $15.9 | 19% below |
| 100 week MA | $14.7 | 13% below |
| 200 week MA | $15.1 | 15% below |
RIVN is in a downtrend: it's below all five of its weekly moving averages, and 15% below its 200-week average.
MED Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $108.3 | $196.7 | +82% |
| 2021 | $196.7 | $204.2 | +3.8% |
| 2022 | $204.2 | $117.1 | -43% |
| 2023 | $117.1 | $67.2 | -43% |
| 2024 | $67.2 | $17.6 | -74% |
| 2025 | $17.6 | $11.0 | -37% |
| 2026 YTD | $11.0 | $12.9 | +16% |
MED has the edge over RIVN on returns for 2026, with the stronger performance.
RIVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $130.0 | $96.8 | -25% |
| 2022 | $96.8 | $19.1 | -80% |
| 2023 | $19.1 | $23.5 | +23% |
| 2024 | $23.5 | $13.7 | -42% |
| 2025 | $13.7 | $20.9 | +53% |
| 2026 YTD | $20.9 | $12.8 | -39% |
RIVN has finished lower in three of the last five years. It's down 39% so far in 2026.